symbol |
XTLB |
会社名 | XTL Biopharmaceuticals Ltd (XTLバイオファ―マシュ―ティカルズ) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Major Pharmaceuticals
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 XTL Biopharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound working through a mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO a known agent for anemia is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias including anemia of kidney disease and cancer-related anemia. XTLバイオファ―マシュ―ティカルズは、イスラエルのバイオ医薬品企業。全身性エリテマト―デス、多発性骨髄腫、統合失調症の治療薬の開発に従事。hCDR1、rHuEPO、SAM-101の治療薬開発プログラムを手掛けるほか、個人使用の治療機器として非薬物・非侵襲性の高血圧症治療装置RESPeRATEの販売を行う。
|
本社所在地 | 5 HaCharoshet St. Raanana 43656 ISR |
代表者氏名 | Shlomo Shalev Spokone Shlomo Shalev Spokone |
代表者役職名 | Chairman of the Board 取締役会会長 |
電話番号 | +972 9-955-7080 |
設立年月日 | 34029 |
市場名 | NASDAQ Small Cap |
ipoyear | ―年 |
従業員数 | 3人 |
url | www.xtlbio.com |
nasdaq_url | https://www.nasdaq.com/symbol/xtlb |
adr_tso | 2810588 |
EBITDA | EBITDA(百万ドル) -1.11700 |
終値(lastsale) | 2.18 |
時価総額(marketcap) | 6127081.84 |
時価総額 | 時価総額(百万ドル) 11.75894 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) ー |
当期純利益 | 当期純利益(百万ドル) 1.07100 |
決算概要 | 決算概要 BRIEF: For the three months ended 31 March 2018 X T L Biopharmaceuticals Ltd (ADR) revenues was not reported. Net income totaled $875K vs. loss of $977K. Net income reflects Finance income increase from $17K to $1.1M (income) Finance expenses decrease of 99% to $6K (expense) General and administrative expenses decrease of 38% to $187K (expense). |